The Latest News on Dangerous Drugs from Ameridose and the New England Compounding Center

Manufacturers of drugs are expected to ensure the drugs are reasonably safe and that patients taking the drugs are warned of any potential risk. Unfortunately, despite the requirements intended to protect consumers, sometimes dangerous drugs are released anyway.

One recent example of a dangerous drugs is a steroid injection produced in a compounding center called the New England Compounding Center (NECC). The NECC’s drug turned out to be a serious public health risk, and the company was forced to stop operations. Its sister company, Ameridose, also had to shut down. 1238929_untitled.jpg

Our North Carolina defective drug attorneys want to warn those who may have been exposed to drugs from NECC or Ameridose of the potential dangers and wish to keep you up-to-date on the latest news on these dangerous drugs.

The NECC, Ameridose and Dangerous Drugs

In early October, a preservative free substance called methylph rednisolone was contaminated with fungus including Asperigillus fumigatus and Exserohilum. The methyl rednisolone and the fungus made their way into as many as 17,000 vials of steroid injection compounded by the NECC.

These 17,000 files of contaminated drugs went out to states including North and South Carolina, as well as California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Maryland, Michigan, Minnesota, New Hampshire, new Jersey, Nevada, New York, Ohio, Pennsylvania, Rhode Island, Tennessee, Virginia, Texas and West Virginia.

Unfortunately, as many as 14,000 people received the contaminated steroid injections from NECC. The consequences of the dangerous drug were devastating — more than 30 patients have died and nearly 500 have been sickened.

NECC suspended operations, facing allegations of violations of state operating guidelines and lawsuits. Its sister company, Ameridose, also agreed with state operators that they would suspend operations. The suspension began on October 10, and at the end of October, the company recalled more than 2,000 drugs after the FDA identified problems with cleanliness and with the sterility of the drugs they were producing.

The Latest Ameridose News
Ameridose is a major supplier for hospitals around the country, and the fact that its operations are shut down is creating shortages. However, when it comes to dangerous drugs, it is essential to do everything possible to ensure that the drugs don’t do harm to consumers.

Ameridose recalled more than 2,000 of its drugs already, although no infection has been linked to their products. However, Ameridose also wishes to reopen and to continue its compounding operation. The date on which they can reopen has already been pushed back three times since the company’s suspension of operations on the 10th.

The latest date that the company was supposed to reopen was November 19, but the most recent Ameridose news from the Boston Globe indicates that this has been pushed back yet again in light of FDA concerns. The FDA released a report identifying problems including the presence of both insects and a bird in a supposedly sterile area where drugs were being packaged and stored.

The behavior of Ameridose and NECC has put many patients at risk due to violations of safety precautions and the release of dangerous drugs. Those who have taken a defective drug supplied by NECC or Ameridose should consider taking legal action with the help of a personal injury attorney.

Contact the Asheville defective product attorneys at Lee Law Offices, P.A. if you or someone close to you has been injured by a defective drug. We offer free consultations to injured consumers in the Carolinas. Call 1-800-887-1965 to speak to an injury lawyer today.

Additional Resources:
Meningitis Outbreak in North Carolina Linked to Tainted Drug Injections, North Carolina Personal Injury Lawyers Blog, November 1, 2012

Meningitis Lawsuits against NECC Expected for Personal Injury and Wrongful Death in Tennessee, Michigan, Virginia and Other States, Food Poisoning Bulletin, October 10, 2012

Contact Information